HEPATITES PROBABLEMENT DUES A L'EXIFONE (ADLONE®)

D. Larrey; P. Biclet; A. Razafimahaleo; C. Degott; B. Devergie; G. Babany; J. F. Mosnier; J. Y. Scoazec; G. Feldmann; D. Pessayre; J. P. Benhamou

HEPATITES PROBABLEMENT DUES A L'EXIFONE (ADLONE®)

D. Larrey, P. Biclet, A. Razafimahaleo, C. Degott, B. Devergie, G. Babany, J. F. Mosnier, J. Y. Scoazec, G. Feldmann, D. Pessayre, J. P. Benhamou

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

Exifone, a drug recently proposed for the treatment of cognitive deficiences of old age, has been marketed in France beginning in april 1988. This report concerns 2 patients who developed jaundice after taking this drug for 2 and 5 months, respectively. Serum aminotransferase was markedly increased. There was no hepatic failure. In both cases, histologic examination of a live sample showed centrilobular hepatocyte necrosis and cholestasis. Necrotic cells were infiltrated with numerous red blood cells and scarce inflammatory cells. These lesions were associated with alterations of the walls of centrilobular veins. Discontinuation of exifone as followed by the prompt disappearance of jaundice. Complete recovery occurred within 6 and 12 weeks, respectively.

Titre traduit de la contribution	Hepatitis probably caused by exifone (Adlone®)
langue originale	Français
Pages (de - à)	397-400
Nombre de pages	4
journal	Gastroenterologie Clinique et Biologique
Volume	13
Numéro de publication	4
état	Publié - 1 janv. 1989
Modification externe	Oui

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{bf0b1f00d08e446e89075548604b4a20,

title = "HEPATITES PROBABLEMENT DUES A L'EXIFONE (ADLONE{\textregistered})",

abstract = "Exifone, a drug recently proposed for the treatment of cognitive deficiences of old age, has been marketed in France beginning in april 1988. This report concerns 2 patients who developed jaundice after taking this drug for 2 and 5 months, respectively. Serum aminotransferase was markedly increased. There was no hepatic failure. In both cases, histologic examination of a live sample showed centrilobular hepatocyte necrosis and cholestasis. Necrotic cells were infiltrated with numerous red blood cells and scarce inflammatory cells. These lesions were associated with alterations of the walls of centrilobular veins. Discontinuation of exifone as followed by the prompt disappearance of jaundice. Complete recovery occurred within 6 and 12 weeks, respectively.",

author = "D. Larrey and P. Biclet and A. Razafimahaleo and C. Degott and B. Devergie and G. Babany and Mosnier, {J. F.} and Scoazec, {J. Y.} and G. Feldmann and D. Pessayre and Benhamou, {J. P.}",

year = "1989",

month = jan,

day = "1",

language = "Fran{\c c}ais",

volume = "13",

pages = "397--400",

journal = "Gastroenterologie Clinique et Biologique",

issn = "0399-8320",

number = "4",

}

TY - JOUR

T1 - HEPATITES PROBABLEMENT DUES A L'EXIFONE (ADLONE®)

AU - Larrey, D.

AU - Biclet, P.

AU - Razafimahaleo, A.

AU - Degott, C.

AU - Devergie, B.

AU - Babany, G.

AU - Mosnier, J. F.

AU - Scoazec, J. Y.

AU - Feldmann, G.

AU - Pessayre, D.

AU - Benhamou, J. P.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Exifone, a drug recently proposed for the treatment of cognitive deficiences of old age, has been marketed in France beginning in april 1988. This report concerns 2 patients who developed jaundice after taking this drug for 2 and 5 months, respectively. Serum aminotransferase was markedly increased. There was no hepatic failure. In both cases, histologic examination of a live sample showed centrilobular hepatocyte necrosis and cholestasis. Necrotic cells were infiltrated with numerous red blood cells and scarce inflammatory cells. These lesions were associated with alterations of the walls of centrilobular veins. Discontinuation of exifone as followed by the prompt disappearance of jaundice. Complete recovery occurred within 6 and 12 weeks, respectively.

AB - Exifone, a drug recently proposed for the treatment of cognitive deficiences of old age, has been marketed in France beginning in april 1988. This report concerns 2 patients who developed jaundice after taking this drug for 2 and 5 months, respectively. Serum aminotransferase was markedly increased. There was no hepatic failure. In both cases, histologic examination of a live sample showed centrilobular hepatocyte necrosis and cholestasis. Necrotic cells were infiltrated with numerous red blood cells and scarce inflammatory cells. These lesions were associated with alterations of the walls of centrilobular veins. Discontinuation of exifone as followed by the prompt disappearance of jaundice. Complete recovery occurred within 6 and 12 weeks, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0024652158&partnerID=8YFLogxK

M3 - Article

C2 - 2737393

AN - SCOPUS:0024652158

SN - 0399-8320

VL - 13

SP - 397

EP - 400

JO - Gastroenterologie Clinique et Biologique

JF - Gastroenterologie Clinique et Biologique

IS - 4

ER -